Erb-B2 Receptor Tyrosine Kinase 2 Peptide 1
Rabbit Monoclonal Antibody
Peptide, Recombinant Full-length, Native Protein
Indirect ELISA (ie, binding of Antibody to biotinylated peptide coated on a NeutrAvidin plate). Note: B50% represents the concentration of Ab required to generate 50% of maximum binding.
Indirect ELISA (ie, binding of Antibody to full-length Antigen coated on plate). Note: B50% represents the concentration of Ab required to generate 50% of maximum binding.
Indirect ELISA (ie, binding of Antibody to full-length Antigen coated on plate). Recombinant ERBB2 antigen, variant 2, from transfected HEK293T cells (Origene, Inc.)Note: B50% represents the concentration of Ab required to generate 50% of maximum binding.
Western Blot using CPTC-ERBB2-1 as primary Ab against lysates from six breast cancer cell lines from the NCI60 cell line collection (lanes 2-7). Also included are molecular wt. standards (lane 1).
Western Blot using CPTC-ERBB2-1 as primary Ab against HEK293T cell lysate containing HER2 variant 1 (from Origene) in lane 2. Also included are molecular wt. standards (lane 1) and the Erbb2-1 Ab as the IgG control (lane 3).
Western Blot using CPTC-ERBB2-1 as primary Ab against HEK293T cell lysate containing HER2 variant 2 (from Origene) in lane 2. Also included are molecular wt. standards (lane 1) and the Erbb2-1 Ab as the IgG control (lane 3).
NCI Identification Number:
Erb-B2 Receptor Tyrosine Kinase 2 Peptide 1
CPTC-ERBB2 Peptide 1
HER2; NEU; NGL; CD340; V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2; Metastatic Lymph Node Gene 19 Protein; Proto-Oncogene C-ErbB-2; Proto-Oncogene Neu; Tyrosine Kinase-Type Cell Surface Receptor; MLN 19; P185erbB2; EC 22.214.171.124; HER-2/Neu; TKR1; C-Erb B2/Neu Protein; Herstatin; Neuroblastoma/Glioblastoma Derived Oncogene Homolog; Receptor Tyrosine-Protein Kinase; ErbB-2; CD340 Antigen
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of
peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family. Four members of the ErbB family have been identified; EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4). EGFR signaling is initiated by ligand binding to the extracellular ligand binding domain. This initiates receptor homo-/hetero-dimerization and autophosphorylation by the intracellular kinase domain, resulting in receptor activation. Following activation, phosphorylation of cytoplasmic substrates occurs and a signaling cascade is initiated that drives many cellular responses, including changes in gene expression, cytoskeletal rearrangement, anti-apoptosis and increased cell proliferation.
NCBI Accession Number:
UniProt Accession Number:
Calculated Isoelectric Point:
No SOPs available.
Get it for free at Adobe.com